Close Menu

NEW YORK (360Dx) – Sciex is counting on its newly announced joint venture with Zhejiang Dian Diagnostics to speed its penetration of the Chinese clinical mass spec market, which a company official said is "set to explode."

Factors like the country's interest in multiplexed diagnostic panels and wellness monitoring have its clinical mass spec space "poised for huge growth," said Aaron Hudson, VP and general manager of Sciex's diagnostics division.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.